BCRX (STOCKS)
BioCryst Pharmaceuticals Inc
$9.500000
-0.060000 (-0.63%)
Prev close: $9.560000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Charles K. Gayer
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,362.55M
- Employees
- 580
- P/E (TTM)
- 7.92
- P/B (TTM)
- -16.83
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.01 | $0.04 | -0.0286 | -74.09% |
|
Sep 2025 (Q3)
|
$0.06 | $0.04 | +0.0241 | +67.13% |
|
Jun 2025 (Q2)
|
$0.04 | $0.01 | +0.0257 | +179.72% |
|
Mar 2025 (Q1)
|
$0.00 | $-0.07 | +0.0695 | +100.00% |
Financial Statements
| Revenues | $874.84M |
| Benefits Costs and Expenses | $607.45M |
| Cost Of Revenue | $19.08M |
| Costs And Expenses | $533.85M |
| Gross Profit | $855.76M |
| Nonoperating Income/Loss | -$73.60M |
| Operating Expenses | $514.77M |
| Selling, General, and Administrative Expenses | $348.65M |
| Research and Development | $166.13M |
| Operating Income/Loss | $340.99M |
| Income/Loss From Continuing Operations After Tax | $263.86M |
| Income/Loss From Continuing Operations Before Tax | $267.39M |
| Income Tax Expense/Benefit | $3.53M |
| Income Tax Expense/Benefit, Current | $4.74M |
| Income Tax Expense/Benefit, Deferred | -$1.21M |
| Net Income/Loss | $263.86M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $263.86M |
| Net Income/Loss Available To Common Stockholders, Basic | $263.86M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $1.26 |
| Diluted Earnings Per Share | $1.21 |
| Basic Average Shares | 209,893,000 |
| Diluted Average Shares | 218,581,000 |
| Assets | $514.16M |
| Current Assets | $404.35M |
| Inventory | $5.40M |
| Other Current Assets | $398.95M |
| Noncurrent Assets | $109.81M |
| Fixed Assets | $8.78M |
| Other Non-current Assets | $101.03M |
| Liabilities | $633.31M |
| Current Liabilities | $196.07M |
| Accounts Payable | $15.83M |
| Wages | $50.86M |
| Other Current Liabilities | $129.38M |
| Noncurrent Liabilities | $437.25M |
| Equity | -$119.15M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$119.15M |
| Liabilities And Equity | $514.16M |
| Net Cash Flow From Operating Activities | $347.37M |
| Net Cash Flow From Operating Activities, Continuing | $347.37M |
| Net Cash Flow From Investing Activities | -$13.69M |
| Net Cash Flow From Investing Activities, Continuing | -$13.69M |
| Net Cash Flow From Financing Activities | -$349.93M |
| Net Cash Flow From Financing Activities, Continuing | -$349.93M |
| Exchange Gains/Losses | $1.27M |
| Net Cash Flow | -$14.99M |
| Net Cash Flow, Continuing | -$16.26M |
| Comprehensive Income/Loss | $262.98M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $262.98M |
| Other Comprehensive Income/Loss | $262.98M |
| Other Comprehensive Income/Loss Attributable To Parent | -$883.00K |